Grifols (GRFS) said Tuesday it received a $21 million grant from the Michael J. Fox Foundation for Parkinson's Research to identify biomarkers that can potentially indicate the likelihood of Parkinson's disease before clinical diagnosis.
Proceeds from the grant will be used for a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years and track the evolution of distinct plasma proteins in patients with Parkinson's disease, according to the company.
The grant is part of the Chronos-PD initiative, which focuses on the discovery of new diagnostic tools and novel treatments, Grifols added.
Price: 7.15, Change: -0.08, Percent Change: -1.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.